Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $33.70, but opened at $34.86. Spyre Therapeutics shares last traded at $35.76, with a volume of 29,172 shares traded.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the stock. Wedbush assumed coverage on shares of Spyre Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $45.00 price target for the company. Evercore ISI assumed coverage on shares of Spyre Therapeutics in a research note on Tuesday, July 16th. They issued an “outperform” rating for the company. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $43.43.
View Our Latest Research Report on SYRE
Spyre Therapeutics Trading Up 6.8 %
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.04. Equities analysts predict that Spyre Therapeutics, Inc. will post -3.68 earnings per share for the current year.
Hedge Funds Weigh In On Spyre Therapeutics
Several large investors have recently bought and sold shares of SYRE. Avoro Capital Advisors LLC bought a new stake in shares of Spyre Therapeutics during the 2nd quarter valued at $43,238,000. Assenagon Asset Management S.A. acquired a new position in Spyre Therapeutics in the third quarter valued at about $33,609,000. Driehaus Capital Management LLC bought a new position in Spyre Therapeutics during the second quarter worth about $16,153,000. Farallon Capital Management LLC bought a new stake in shares of Spyre Therapeutics in the 2nd quarter valued at about $15,658,000. Finally, Logos Global Management LP acquired a new stake in shares of Spyre Therapeutics in the 2nd quarter valued at approximately $13,518,000. 80.39% of the stock is currently owned by institutional investors and hedge funds.
Spyre Therapeutics Company Profile
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Recommended Stories
- Five stocks we like better than Spyre Therapeutics
- How to Calculate Inflation Rate
- Texas Roadhouse Stock Steering for New Highs This Year
- Roth IRA Calculator: Calculate Your Potential Returns
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What Are Dividend Challengers?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.